Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 4—April 2021
Dispatch

Low-Level Middle East Respiratory Syndrome Coronavirus among Camel Handlers, Kenya, 2019

Author affiliations: US Centers for Disease Control and Prevention, Nairobi, Kenya (P.M. Munyua, E. Hunsperger, M.A. Widdowson); University of Nairobi, Nairobi (I. Ngere); Washington State University, Nairobi (I. Ngere, M.K. Njenga);; County Government of Marsabit, Marsabit, Kenya (A. Kochi); Kenya Ministry of Health, Nairobi (P. Amoth, A. Mwatondo);; Kenya Medical Research Institute, Nairobi (L. Mwasi); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Tong, N. Thornburg)

Cite This Article

Abstract

Although seroprevalence of Middle East respiratory coronavirus syndrome is high among camels in Africa, researchers have not detected zoonotic transmission in Kenya. We followed a cohort of 262 camel handlers in Kenya during April 2018–March 2020. We report PCR-confirmed Middle East respiratory coronavirus syndrome in 3 asymptomatic handlers.

Since the first human case of Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012, the World Health Organization has reported 2,494 infections and 858 deaths (case-fatality ratio 34.4%) in persons across 27 countries in the Middle East, Europe, Asia, and North America (1). Dromedary camels (Camelus dromedarius) are the known reservoirs of the virus (2,3). Most human cases result from direct or indirect transmission of virus from camels or human-to-human transmission in healthcare settings; researchers have also documented limited secondary transmission to household contacts (4). Occupational direct contact with camels is a risk factor for primary MERS-CoV infection (5). Camel workers and herders have a 0%–50% seroprevalence of MERS-CoV, generally higher than that of the general population in Saudi Arabia (4,6).

Although infection is widespread among dromedary camels, zoonotic transmission from camels to humans is sporadic, and disease prevalence among humans is not directly proportional to potential exposure to infected camels (4,5,7). Although >65% of the world’s dromedary camels live in Africa, on that continent MERS-CoV seroprevalence in humans is low (0.2%), with no documented cases of acute human infection (8,9). Furthermore, studies in the Africa region have identified MERS-CoV RNA in 11%–16% of camels and in 80%–95% of seropositive camels (911). To determine whether MERS-CoV infections occur in humans in a region with high seroprevalence among camels, we studied a cohort of 262 camel handlers in Kenya.

The Study

Figure 1

Locations of enrolled households in study on MERS-CoV, Marsabit County, Kenya, 2018–2020. Black circles indicate participating households; red circles indicate households with cases. Inset shows location of Marsabit County within Kenya. MERS-CoV, Middle East respiratory syndrome coronavirus.

Figure 1. Locations of enrolled households in study on MERS-CoV, Marsabit County, Kenya, 2018–2020. Black circles indicate participating households; red circles indicate households with cases. Inset shows location of Marsabit County within...

Figure 2

Types and frequency of contacts with camels among participants in study on Middle East respiratory syndrome coronavirus, Marsabit County, Kenya, 2018–2020.

Figure 2. Types and frequency of contacts with camels among participants in study on Middle East respiratory syndrome coronavirus, Marsabit County, Kenya, 2018–2020.

During April 2018–March 2020, we enrolled participants on a rolling basis from 32 camel-owning households in Marsabit County, northern Kenya (Figure 1). We defined a camel handler as any person in the household who had contact with camels (Figure 2). This study was approved by the Scientific and Ethical Review Committee of Kenya Medical Research Institute (approval no. SSC3472), the Institutional Review Board of Washington State University (approval no. 16245), and the US Centers for Disease Control and Prevention (approval no. 7065). We obtained written informed consent from all participants.

We conducted monthly visits with the participants. At each visit, we collected nasopharyngeal and oropharyngeal swab samples from each participant. We also administered a questionnaire to each participating camel handler to identify signs and symptoms of possible respiratory illness during the previous 30 days. In addition, we recorded occurrences of respiratory illness among their household members. Participants belonged to 32 households with a median of 6 persons (interquartile range [IQR] 1–8 persons) and 32 camels (IQR 2–48 camels) at enrollment. The median age of these participants was 19 years (IQR 11–38 years). Most (67.2%) participants were male, of whom 39.3% were employed as camel workers and 38.2% were school going household members (Table 1). All participants handled camels. The most frequent interactions were herding (74.4%), cleaning barns (67.9%), feeding (67.6%), and milking (63.7%) (Figure 2).

We stored the swab samples in virus transport media and tested them for MERS-CoV by reverse transcription PCR (RT-PCR) at the Kenya Medical Research Institute (Nairobi, Kenya) as described previously (12). We conducted real-time RT-PCR selective for the upstream region envelope and 2 distinct regions of nucleocapsid genes on total nucleic acid extracted from 200 μL of sample. We defined a positive sample by positivity of all 3 PCRs.

We tested 1,369 samples from 262 camel handlers during the 2-year follow-up period. Participants had a median of 43.6% of monthly follow-up visits (IQR 8%–75%). Three (1.1%) participants (cases 1–3) tested positive for MERS-CoV by RT-PCR. The cycle threshold (Ct) values for case 1 were 38.9 for the upstream envelope, 37.7 for the nucleocapsid 2, and 39.3 for the nucleocapsid 3 genes; for case 2, the values were 39.7 for the upstream envelope, 36.9 for the nucleocapsid 2, and 39.8 for the nucleocapsid 3 genes; for case 3, the values were 35.6 for the upstream envelope, 36.0 for the nucleocapsid 2, and 36.8 for the nucleocapsid 3 genes. We detected all 3 cases during July–September 2019 (Table 2).

Case 1 was in a woman 20 years of age who enrolled in June 2019 and had 9 monthly follow-up visits. She participated in the study with 11 other members of the household, all of whom tested negative for MERS-CoV throughout the follow-up period. Case 2 was in a man 49 years of age who enrolled in May 2019 and had 7 monthly follow-up visits. He participated in the study with 6 of his 10 household members; all the participants in his household tested negative for MERS-CoV. Case 3 was in a man 22 years of age who enrolled in May 2018 and had 12 monthly follow-up visits. He participated in the study with 3 of his 9 household members; the participants in his household tested negative for MERS-CoV. None of the 3 with positive results tested positive for MERS-CoV in the subsequent months.

All of the 3 with positive results were asymptomatic at diagnosis and had no concurrent conditions or histo-ry of travel outside of the county or country in the previ-ous month. None of them or their household members had respiratory illness before or after diagnosis.

Conclusions

We report 3 PCR-confirmed cases of MERS-CoV in humans in Kenya; these cases met the World Health Organization case definition of MERS-CoV infection (13). All 3 persons were asymptomatic before and after diagnosis; this finding supports previous data suggesting that the virus causes no or mild disease in Africa compared with the Middle East and Asia, perhaps because of the younger age of most camel herders in Africa (4,8,9). Our findings are limited by the high Ct values (>35) of all cases, a level which some experts might not consider to be positive. However, because these patients had Ct values <40 for 3 distinct MERS-CoV genes, we feel confident that these are unlikely to be false positive results. Researchers have observed low upper respiratory tract RNA concentrations in asymptomatic patients and contacts of MERS-CoV patients (14). In contrast to studies conducted in the Middle East, we found no evidence of human-to-human transmission; a total of 20 household members of the 3 patients tested negative for MERS-CoV before and after their household member’s diagnosis. However, we might have missed some infections that occurred between follow-up visits. Furthermore, not all household members were enrolled in the study. In addition, serologic assessment of MERS-CoV T-cell responses might detect mild and asymptomatic MERS-CoV cases (15). Finally, the low (0.2%) seroprevalence among participants who had high exposure to camel herds with MERS-CoV circulation suggest a low level of zoonotic camel-to-human transmission. We previ-ously found no antibodies against MERS-CoV in camel herders despite high seroprevalence among camels in this community (9).

In conclusion, we confirmed zoonotic transmis-sion of MERS-CoV from camels to handlers in Kenya. Focused surveillance is needed to detect these rare in-fections when they occur.

Dr. Munyua is an epidemiologist within the Division of Global Health Protection, Global Health, US Centers for Disease Control and Prevention, Nairobi. Her research interests include infectious and zoonotic diseases.

Top

Acknowledgments

We thank Arithi Mutembei, Jack Omolo, Diba Denge, Boru Dub Wato, Millicent Minayo, Moshe Alando, Doris Marwanga, and Cynthia Awuor for their contribution to data and specimen collection. We appreciate the camel herders in Marsabit who participated in this study. We also thank the administrative team at the Washington State University Global Health Program for facilitating all study logistics.

This project was funded by the US Centers for Disease Control and Prevention under the research co-operative agreement with Washington State University (grant no. 1U01GH002143).

Top

References

  1. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) summary updates, November 2019. 2019 [cited 2020 Jul 6]. https://www.who.int/emergencies/mers-cov/en
  2. Ali  MA, Shehata  MM, Gomaa  MR, Kandeil  A, El-Shesheny  R, Kayed  AS, et al. Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. Emerg Microbes Infect. 2017;6:e1. DOIPubMedGoogle Scholar
  3. Reusken  CB, Farag  EA, Jonges  M, Godeke  GJ, El-Sayed  AM, Pas  SD, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill. 2014;19:20829. DOIPubMedGoogle Scholar
  4. Grant  R, Malik  MR, Elkholy  A, Van Kerkhove  MD. A review of asymptomatic and subclinical Middle East respiratory syndrome coronavirus infections. Epidemiol Rev. 2019;41:6981. DOIPubMedGoogle Scholar
  5. Hui  DS, Azhar  EI, Kim  YJ, Memish  ZA, Oh  MD, Zumla  A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18:e21727. DOIPubMedGoogle Scholar
  6. Alshukairi  AN, Zheng  J, Zhao  J, Nehdi  A, Baharoon  SA, Layqah  L, et al. High prevalence of MERS-CoV infection in camel workers in Saudi Arabia. MBio. 2018;9:e01985-18. DOIPubMedGoogle Scholar
  7. Hemida  MG, Al-Naeem  A, Perera  RA, Chin  AW, Poon  LL, Peiris  M. Lack of middle East respiratory syndrome coronavirus transmission from infected camels. Emerg Infect Dis. 2015;21:699701. DOIPubMedGoogle Scholar
  8. Liljander  A, Meyer  B, Jores  J, Müller  MA, Lattwein  E, Njeru  I, et al. MERS-CoV antibodies in humans, Africa, 2013–2014. Emerg Infect Dis. 2016;22:10869. DOIPubMedGoogle Scholar
  9. Munyua  P, Corman  VM, Bitek  A, Osoro  E, Meyer  B, Müller  MA, et al. No serologic evidence of Middle East respiratory syndrome coronavirus infection among camel farmers exposed to highly seropositive camel herds: a household linked study, Kenya, 2013. Am J Trop Med Hyg. 2017;96:131824. DOIPubMedGoogle Scholar
  10. Chu  DKW, Hui  KPY, Perera  RAPM, Miguel  E, Niemeyer  D, Zhao  J, et al. MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proc Natl Acad Sci U S A. 2018;115:31449. DOIPubMedGoogle Scholar
  11. Corman  VM, Jores  J, Meyer  B, Younan  M, Liljander  A, Said  MY, et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013. Emerg Infect Dis. 2014;20:131922. DOIPubMedGoogle Scholar
  12. Corman  VM, Ölschläger  S, Wendtner  CM, Drexler  JF, Hess  M, Drosten  C. Performance and clinical validation of the RealStar MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA. J Clin Virol. 2014;60:16871. DOIPubMedGoogle Scholar
  13. World Health Organization. Middle East respiratory syndrome case definition for reporting to WHO. 2017 [cited 2020 Oct 2]. https://www.who.int/csr/disease/coronavirus_infections/mers-interim-case-definition.pdf
  14. Drosten  C, Meyer  B, Müller  MA, Corman  VM, Al-Masri  M, Hossain  R, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:82835. DOIPubMedGoogle Scholar
  15. Mok  CKP, Zhu  A, Zhao  J, Lau  EHY, Wang  J, Chen  Z, et al. T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infect Dis. 2020;S1473-3099(20)30599-5.DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid2704.204458

Original Publication Date: March 11, 2021

1These senior authors contributed equally to this article.

2Current affiliation: Institute of Tropical Medicine, Antwerp, Belgium.

Table of Contents – Volume 27, Number 4—April 2021

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Peninah Munyua, US Centers for Disease Control and Prevention, PO Box 606, Nairobi 00621, Kenya

Send To

10000 character(s) remaining.

Top

Page created: February 17, 2021
Page updated: March 18, 2021
Page reviewed: March 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external